Agreement in the form of an exchange of letters amending Table I annexed to Protocol 2 to the Agreement between the European Economic Community and the Republic of Iceland

For the products listed in Table II of Protocol N° 2 to the Agreement, the Republic of Iceland shall abolish, in accordance with the timetable laid down in Article 3, the difference between:

Besides this, the table in recital 86 shows that the market share of the other Community producers also decreased, to a significant extent, during the period under consideration.

TABLES RELATING TO AID GRANTED TO PRODUCER ORGANIZATIONS UNDER ARTICLE 14 (1), (2) AND (3) OF REGULATION (EEC) No 1035/72 Serial number (1): Producer organization:

To permit evaluation of results records must be shown on process control charts or tables, containing at least the last 13 weekly test results in order.

The table also shows that the euro-effect provides a temporary boost to sales over the period 1997 to 2000 and that from 2000 to 2002 consumption is forecast to be lower.

The efficacy data from studies AVF0780g and AVF2192g investigating Avastin in combination with 5-FU/ FA-chemotherapy are summarised in Table 4.

Agreement in the form of an exchange of letters amending Tables I and II annexed to Protocol 2 to the Agreement between the European Economic Community and the Swiss Confederation

Respiratory, thoracic and mediastinal disorders (see section 4.4) Pneumonitis, pneumonia, interstitial pneumonia, Acute Respiratory Distress Syndrome (ARDS), acute diffuse infiltrative pulmonary Not known:

It is no longer in the Community's interest to maintain a Community tariff quota on some of the products covered by the above Regulation, and those products should therefore be removed from the table in Annex I.

Known and theoretical interactions with selected antiretrovirals and non-antiretroviral medicinal products are listed in the table below.

Whereas the measures provided for in this Regulation are in accordance with the opinion of the tariff and statistical nomenclature section of the Customs Code Committee as regards product No 2 in the annexed table,

Whereas the measures provided for in this Regulation are in accordance with the opinion of the tariff and statistical nomenclature section of the Customs Code Committee as regards products Nos 1, 2, 4 in the annexed table,

Information relating to operations not included in the general budget of the European Communities and the foreseeable development of the various categories of Community own resources are set out, by way of indication, in separate tables.

Whereas the tariff and statistical nomenclature section of the Customs Code Committee has not delivered an opinion with the time limit set by its chairman as regards products Nos 3, 5, 6, 7 in the annexed table;

The effects of FABLYN on fracture incidence (table 2) were examined through 5 years; and BMD and bone biomarkers in postmenopausal women with osteoporosis were examined through 3 years in the PEARL study.

The Agreement in the form of an exchange of letters amending Tables I and II annexed to Protocol 2 to the Agreement between the European Economic Community and the Kingdom of Norway is hereby approved on behalf of the Community.

It is no longer in the Community's interest to maintain a Community tariff quota on some of the products covered by the above Regulation, and those products should therefore be removed from the table in Annex I;

This shows that over the period considered, the exporting producers increased their sales volume by 123 % in this segment whereas the Community industry only managed to increase its sales volume by 10 %.

When using the table, the values of the tolerable negative errors shown as percentages in the table, calculated in units of volume, shall be rounded up to the nearest one-tenth of a millilitre."

• The need for a guidance table highlighting pre-treatment measurements of serum creatinine, creatinine clearance, proteinuria, hepatic enzymes, ferritin, such as:

When using the table, the values of the tolerable negative errors shown as percentages in the table, calculated in units of weight or volume, shall be rounded up to the nearest one tenth of a gramme or millilitre.

When using the table, the values of the tolerable negative errors shown as percentages in the table, calculated in units of weight or volume, shall be rounded up to the nearest one-tenth of a gram or millilitre.

Whereas Tables I and II annexed to Protocol 2 to the Agreement between the European Economic Community and the Kingdom of Norway [1] should be amended and the Agreement in the form of an exchange of letters which has been negotiated to that end should be approved,

Whether further testing of the same or additional sero-conversion panels is conducted by the notified body or by the manufacturer the results shall confirm the initial performance evaluation data (see Table 1).

Whereas Table I annexed to Protocol 2 to the Agreement between the European Economic Community and the Republic of Iceland [1] should be amended and the Agreement in the form of an exchange of letters which has been negotiated to that end should be approved,

Whereas Tables I and II annexed to Protocol 2 to the Agreement between the European Economic Community and the Swiss Confederation [1] should be amended and the Agreement in the form of an exchange of letters which has been negotiated to that end should be approved,

Tables 1 and 2 also show adverse reactions in patients treated for 3 years with oral ibandronic acid 2.5 mg daily in the anti-fracture study (MF4411).

18 FOLFOX-4 in terms of progression-free survival in the per-protocol population and intent-to-treat population (see Table 8).

Adults: the recommended dose of CELSENTRI is 150 mg, 300 mg or 600 mg twice daily depending on interactions with co-administered antiretroviral therapy and other medicinal products (see Table 2 in Section 4.5).

COUNCIL REGULATION (EEC) No 2563/76 of 20 July 1976 approving the Agreement in the form of an exchange of letters amending Tables I and II annexed to Protocol 2 to the Agreement between the European Economic Community and the Kingdom of Norway

the schedules of price differentials according to milk fat content mentioned in Article 3 (4), note 3 of the Protocol regarding certain milk powders and (1)The terms "acceptance" or "accepted" as used in this Article include the completion of any domestic procedures necessary to implement the provisions of this Arrangement. (2)For the purpose of this Arrangement, the term "government" is deemed to include the competent authorities of the European Economic Community. Article 3 (4), note 1, of the Protocol regarding milk fat, contained in Annexes Ib and IIb respectively,

The Hellenic Republic shall apply the provisions laid down in the table contained in Article 1 (3) of Protocol 1 to the Agreement to all products covered by Chapters 48 and 49 of the Common Customs Tariff originating in Iceland and not listed in Annex I.

COUNCIL REGULATION (EEC) No 3396/83 of 14 November 1983 on the conclusion of the Agreement in the form of an exchange of letters amending Table II annexed to Protocol 2 of the Agreement between the European Economic Community and the Swiss Confederation

calculated on the basis of the last column (total) of the financial table annexed to the Commission Decision approving the programming document or annexed to the decision referred to in the first subparagraph of Article 48(1), as last amended.

The efficacy results for relevant endpoints analysed at 2 years post-enrolment and at end of study (median duration of follow-up = 3.6 years) in the per-protocol population are presented in the Table 1.

Based on in vitro studies and pharmacokinetic data obtained in healthy volunteers the following table describes interference with laboratory tests that may be observed following a 5 g dose of hydroxocobalamin.

products composed of pieces, fragments or grains, the unit weight of which does not exceed one third of the tolerable negative error corresponding to the nominal weight of the contents of the prepackage in the Class "A" column of the table in 2.4,

COUNCIL REGULATION (EEC) No 2562/76 of 20 July 1976 approving the Agreement in the form of an exchange of letters amending Table I annexed to Protocol 2 to the Agreement between the European Economic Community and the Republic of Iceland

COUNCIL REGULATION (EEC) No 2566/76 of 20 July 1976 approving the Agreement in the form of an exchange of letters amending Tables I and II annexed to Protocol 2 to the Agreement between the European Economic Community and the Swiss Confederation

If Member States opt for regionalised rural development programming, that overall amount may be the subject of a separate decision containing a consolidated financial table for all the rural development programmes of the Member State concerned.

Clinical trial data and post-marketing data Table 3 presents adverse reactions by system organ class and by frequency category based on experience with glimepiride and other sulphonylureas.

Each Member State shall keep available to the Commission all the information marked "X", "A" or "B" by budget item in the table in Annex I in respect of each individual operation making up the payments by and receipts of the EAGGF Guarantee Section.

The volume of table wine and wine suitable for yielding table wine produced shall be only that given as wine in the column headed 'Table wines' in the declaration of quantities produced referred to in Table C of Commission Regulation (EC) No 1282/2001(5).

"The Contracting Parties to the Agreement between the European Economic Community and the Republic of Iceland signed on 22 July 1972 have examined in the Joint Committee the possibility of making certain amendments to Table I annexed to Protocol 2 to the said Agreement.

Post-marketing experience Clinically significant adverse reactions are listed in Table 6, if they have been reported during post approval use of VELCADE and may or may not have been reported in clinical trials.

The possibility of shortening treatment duration to 16 weeks in genotype 2 or 3 patients was examined based on a sustained virological response observed in patients with rapid virological response by week 4 in study NV17317 (see Table 10).

"The Contracting Parties to the Agreement between the European Economic Community and the Swiss Confederation signed on 22 July 1972 have examined in the Joint Committee the possibility of making certain amendments to Tables I and II annexed to Protocol 2 to the said Agreement.

However, subjects with baseline CD4 > 100 cells/ mm3, baseline HIV-1 RNA < 5.0 log10 copies/ ml, ≤ 10 prior ARVs, and/ or other active ARVs in their OB regimen were more likely to achieve a HIV-1 RNA of < 400 copies/ ml (or < 50 copies/ ml) on either treatment.

The following table 5 describes safety data from 340 patients with previously untreated multiple myeloma who received VELCADE (1.3 mg/ m2) in combination with melphalan (9 mg/ m2) and prednisone (60 mg/ m2) in a prospective Phase III study.